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[57] ABSTRACT
Microspheres for radiation therapy of a mammal which 
have a non-radioactive isotope which emits beta or 
gamma radiation of therapeutic intensity upon being 
irradiated. The microspheres also contain elements 
which do not become radioactive upon irradiation. The 
chemical durability of the microspheres is such that 
they do not release a significant amount of radiation 
emitting radioisotope into the mammal’s system upon 
administration. Microspheres containing phosphorus or 
yttrium; and carbon, nitrogen, fluorine, sodium, magne­
sium, aluminum, silicon, potassium, vanadium, manga­
nese, gallium, niobium, iodine and/or lead.
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MICROSPHERES FOR RADIATION THERAPY
This is a continuation application of application Ser. 
No. 280,005, filed Dec. 5, 1988, now abandoned, which 
was a continuation application of application Ser. No. 
673,123, filed Nov. 19, 1984, now U.S. Pat. No. 
4,789,501.
BACKGROUND OF THE INVENTION
In still another application, microspheres have been 
prepared comprising a ceramic material and having a 
radioactive isotope incorporated into the ceramic mate­
rial. While the release of radioactive isotopes from a 
radioactive coating into other parts of the human body 
may be eliminated by incorporating the radioisotopes 
into ceramic spheres, the latter product form is never­
theless not without its disadvantages. Processing of 
these ceramic microspheres is complicated because 
10 potentially volatile radioactivity must be added to ce­
ramic melts and the microspheres must be produced and 
sized while radioactive, with concomitant hazards of 
exposure to personnel and danger of radioactive con­
tamination of facilities.
Consequently, a need has remained for a microsphere 
which is useful in the treatment of cancer or tumor 
bearing tissue, but which will not release a radioactive 
coating or isotope into remote parts of the body of the 
patient after administration, will not require any techni­
cians to handle any radioactive materials during the 
formation and spheroidization of the microsphere and 
which have a density which will permit the micro­
spheres to be suspended in a fluid suitable for injection 
into a human.
SUMMARY OF THE INVENTION
Among the several objects of the invention, therefore 
may be noted the provision of a novel microsphere for 
use in radiation therapy; the provision of such a micro­
sphere wherein the radioactive isotope is uniformly 
distributed throughout the microsphere material; the 
provision of such a microsphere wherein there is no 
significant release of the radioactive isotope from the 
microsphere into the body of the patient; the provision 
of such a microsphere in which the microsphere is com­
pletely non-radioactive until irradiated for use in ther­
apy; the provision of such a microsphere which con­
tains a stable element or isotope that can be activated to 
a beta or gamma radiation emitting isotope by neutron 
irradiation; the provision of such a microsphere which 
contains a number of stable elements or isotopes that 
which forms a number of beta or gamma radiation emit­
ting isotopes simultaneously during neutron activation, 
thereby permitting wide variation in the rate at which 
the radiation is delivered to the body; the provision of 
such a microsphere wherein the density of the sphere is 
substantially less than that of yttrium oxide particles; the 
provision of formulations for treatment of tumors by
The present invention relates generally to micro­
spheres useful in the treatment of cancerous and tumor 
bearing tissue and more particularly to novel glass mi­
crospheres useful in this treatment.
In the treatment of patients with certain kinds of 15 
cancer, methods are known in which radioactive parti­
cles are introduced intravascularly in order to trap the 
radioactive particle at a particular site for its radiation 
effect. According to this technique, a small quantity of 
the radioactive particles are injected into the patient 
and a diffuse, homogeneous field of radiation within a 
selected region of the body is achieved by permanent 
lodgement of the particles in the capillary bed of the 
proposed area, typically the location of a tumor. In 
early applications of this technique, yttrium oxide pow­
der was suspended in a viscous medium prior to admin­
istration. Yttrium was selected for the technique be­
cause of its suitable characteristics: it emits nearly 100 
percent beta radiation. See, e.g., Nolan, et al., Intravas­
cular Particulate Radioisotope Therapy”. The American 
Surgeon 35: 181-188 (1969) and Grady, et. al., Intra-Ar­
terial Radioisotopes to Treat Cancer”, American Sur­
geon 26: 678-684 (1960). This method is not totally 
satisfactory, however. Two disadvantages of yttrium 
oxide powder are its high density (5.01 gm/cm3) and 
irregular particle shape. The high density of pure yt­
trium oxide powder makes it difficult to keep the parti­
cles in suspension in the liquids used to inject them into 
the body, and accelerates their tendency to settle in the 40 
blood stream prior to reaching the desired tumor. The 
sharp corners and edges of yttrium oxide particles also 
irritate surrounding tissue in localized areas, and inter­
fere with the uniform distribution of the radioactive 
particles in the tumor to be treated.
In later applications, the particles used have been 
microspheres composed of an ion exchange resin, or 
crystalline ceramic core, coated with a radioactive iso­
tope such as P-32 or Y-90. Both ion exchange resin and . . .  , . . r
crystalline ceramic microspheres offer the advantage of 50 parenteral administration; and the provision of pro-






having a density much lower than that of yttrium oxide 
particles, and the ion exchange resin offers the addi­
tional advantage of being particularly easy to label. See, 
e.g., Zielinski and Kasprzyk, “Synthesis and Quality 
Control Testing of 32P labelled Ion Exchange Resin 
Microspheres for Radiation Therapy of Hepatic Neo­
plasms”, Int, J. Appl. Radial Isot. 34: 1343-1350 (1983). 
However, whenever a microsphere comprises a core 
material having an external surface coating which con­
tains the radioactive isotope there is a risk that the radi­
oactive coating may separate from the underlying mi­
crosphere core. Any mechanical breakage of the coat­
ing can release unwanted radioactivity to other parts of
55
60
cesses for radiation therapy as well as the anufacture 
of microspheres of the present invention.
Briefly, therefore, the present invention is directed to 
novel radioactive microspheres which may be used for 
radiation therapy of a mammal. These radioactive mi­
crospheres comprise a biologically compatible glass 
material containing a beta or gamma radiation emitting 
radioisotope distributed substantially uniformly 
throughout the glass.
In another aspect, the present invention is directed to 
radioactive microspheres adapted for radiation therapy 
of a mammal. These radioactive microspheres comprise 
a biologically compatible glass material containing a 
beta or gamma radiation emitting radioisotope distrib-the human body which is highly undesirable. Further _ . , ,
disadvantages are presented by the special handling and 65 uted substantially uniformly throughout the glass. The 
precautions that are necessary to coat a radioactive microsphere is substantially spherical m shape and has a
isotope onto a crystalline ceramic core, or to label ion diameter in the range of about 5 to about 75 microme-
exchange resin. ters-
5,302,369
Another aspect of the present invention is directed to 
radioactive microspheres adapted for radiation therapy 
of a mammal. These radioactive microspheres comprise 
a biologically compatible glass material having a radioi­
sotope emitting a therapeutic amount of beta or gamma 
radiation and a balance of elements which either do not 
become radioactive during neutron irradiation or which 
have a half-life that is sufficiently short so that the ele­
ment does not emit a significant amount of beta or 
gamma radiation at the time of administration.
A further aspect of the present invention is directed 
to novel microspheres adapted for radiation therapy of 
a mammal. These microspheres comprise a biologically 
compatible glass having an isotope distributed substan­
tially uniformly throughout the glass. These micro­
spheres are substantially spherical in shape and the iso­
tope is selected from the group consisting of phos­
phorus-32 and yttrium-90 and stable isotopes which are 
activatable by neutron irradiation to produce phos- 
phous-32 or yttrium-90.
A further aspect of the present invention is directed 
to novel glass microspheres adapted for radiation ther­
apy of a mammal. These glass microspheres comprise 
silica, alumina and yttria and have a diameter of less 
than about 75 micrometers.
A still further aspect of the present invention is di­
rected to a method of preparing a microsphere for use in 
a radiation therapy procedure. The method comprises 
irradiating a microsphere comprising a glass material 
containing a stable element or isotope and thereby acti­
vating the element or isotope to a beta or gamma radia­
tion emitting isotope.
A still further aspect of the present invention is di­
rected to a method of radiation therapy for a mammal. 
This method comprises administering to the mammal, 
glass microspheres containing a beta or gamma radia­
tion emitting radioisotope distributed substantially uni­
formly throughout the glass.
A further aspect of the present invention is directed 
to novel microspheres adapted for irradiation and subse­
quent use in radiation therapy of a mammal. The micro­
spheres comprise a glass material containing phospho­
rus or yttrium distributed substantially uniformly 
throughout the glass and a balance of elements selected 
from the group consisting of those elements which ei- 45 
ther do not become radioactive during neutron irradia­
tion or which have a half-life that is sufficiently short so 
that the element does not emit a significant amount of 
beta or gamma radiation at the time of administration.
A further aspect of the present invention is directed 
to novel microspheres adapted for radiation therapy of 
a mammal. These microspheres comprise a glass mate­
rial containing an element distributed substantially uni­
formly throughout the glass and which, upon being 
subjected to an effective amount of neutron irradiation, 
emits a therapeutic intensity and amount of beta or 
gamma radiation. The balance of elements contained by 
the microsphere are selected from the group consisting 
of carbon, nitrogen, oxygen, fluorine, sodium, magne­
sium, aluminum, silicon, potassium, vanadium, manga­
nese, gallium, niobium, iodine, lead, titanium, copper, 
germanium, and zirconium.
A still further aspect of the present invention is di­
rected to a radioactive glass material adapted for radia­
tion therapy of a mammal. The glass material comprises 65 
an yttrium oxide-aluminosilicate glass having a compo­
sition lying substantially within a quadrilateral region of 











silica system. This quadrilateral region of the ternary 
diagram is defined by its four corners having the follow­
ing combination of weight proportions of the compo­
nents: 20% silica, 10% alumina, 70% yttria; 70% silica, 
10% alumina, 20% yttria; 70% silica, 20% alumina, 
10% yttria; and 20% silica, 45% alumina, 35% yttria.
A still further aspect of the present invention is di­
rected to a glass material adapted for radiation therapy 
of a mammal. The glass material comprises between 
about 50 and about 70 wt. % silica, between about 1 and 
about 17 wt. % alumina; between about 5 and about 9 
wt. % magnesia; and between about 2 and about 10 wt. 
% phosphorus pentoxide.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a ternary composition diagram of the yttria- 
alumina-silica system with a cross-hatched region desig­
nating preferred glasses for use in the microspheres of 
the present invention.
FIG. 2 is a series of plots showing the weight propor­
tion of elemental phosphorus leached from various mi­
crospheres of the invention as a function of time of 
exposure to deionized water at 50° C.
FIG. 3 is a plot similar to FIG. 2 showing leaching of 
radioactive phosphorus from microspheres exposed to 
human blood plasma at 37° C.
FIG. 4 is a plot of solution activity of Y-90 divided by 
initial Y-90 activity versus time for a YAS glass sample 
evaluated in Example 2.
FIG. 5 is a plot of decay of leachate from a YAS glass 
sample versus time containing the results of Example 2.
DESCRIPTION OF THE PREFERRED 
EMBODIMENT
In accordance with the present invention, novel mi­
crospheres have been devised for use in the therapy of 
certain cancers and tumor bearing tissue. These novel 
microspheres comprise a glass material having a stable 
element which can be activated by neutron irradiation 
to produce a beta or gamma radiation emitting isotope 
distributed substantially uniformly throughout the 
glass. Thus, these novel microspheres may be manufac­
tured and sized before radioactivity is induced, thereby 
avoiding the necessity of either adsorbing a radioele­
ment onto the microsphere surface, or adding radioele­
ments to a high temperature melt and spheroidizing and 
sizing the particles while intensely radioactive.
Various biologically compatible glasses may be used 
in preparing the microspheres of the present invention. 
Preferably, these glasses are good solvents for small 
amounts of nearly all oxides and have sufficient chemi­
cal durability so that, after the microspheres are admi- 
nisted to a target portion of the patient’s body, no signif­
icant amount of any radioactive isotope is lost from the 
patient’s body or transformed to other parts of the pa­
tient’s system. It is further preferred that the glasses do 
not incorporate any elements that may cause the micro­
sphere to emit any significant amount of undesired radi­
ation. In accordance with a preferred embodiment of 
the present invention, many aluminosilicate glasses and 
lead silicate glasses have been found to be good solvents 
for small amounts of nearly all oxides, thereby permit­
ting great versatility: the dose and profile of the radia­
tion emitted by microsphere may be controlled by in­
corporating elements having the desired emission cha- 
rateristics after irradiation. Many aluminosilicate and 
lead silicate glasses also have sufficient chemical dura­
bility to prevent tile loss of a significant amount of the
radioactive isotope into the patient’s system after the 
microsphere is administered, yet do not need to contain 
any elements that may cause the microsphere to emit a 
significant amount of undesired radiation. Various alu­
minosilicate glasses and lead silicate glasses thus may be 
used in accordance with a preferred embodiment of the 
present invention. For instance, preferred glasses incor­
porating yttrium are yttrium oxide-aluminosilicate 
(YAS) glass compositions lying substantially within a 
quadrilateral region of the ternary composition diagram 
of the yttria-alumina-silica system, the quadrilateral 
region being defined by the four corners having the 
following specified weight proportions of each of the 
components:
5





This quadrilateral region is shown in FIG. 1. The den­
sity of the YAS glasses is preferably within the range of 
about 2.7 to about 3.9 grams/cc. By way of further 
example, preferred glasses incorporating phosphorus 
comprise silica, alumina, magnesia and phosphorus con­
taining between about 50 and about 70 wt. % silica,
negative impact on healthy tissue surrounding the can­
cerous or tumor bearing tissue. In this regard, it is pre­
ferred that the constituent elements of the glass be se­
lected so that the therapeutic radiation emitting radio- 
5 isotopes are the only constituent isotopes which may 
emit a significant amount of radiation beyond a rela­
tively short period of time, e.g., on the order of about 1 
week or less. Elements such as yttrium and phosphorus 
which form radioisotopes having a half-life greater than 
10 about two days and less than about 30 days are particu­
larly preferred as the elements which emit therapeutic 
radiation. The balance of the constituent elements of the 
glass are preferably selected so that when administered, 
the microsphere does not emit any significant amount of 
15 radiation other than that emitted by Y-90 or P-32. This 
result may be accomplished by selecting a glass compo­
sition that contains yttrium-89 or phosphorus-31 and a 
balance of elements which either do not become radio­
active during neutron irradiation or which have a suffi- 
20 ciently short half-life so as not to emit a significant 
amount of beta or gamma radiation at the time of admin­
istration. Elements which either do not become radioac­
tive during neutron irradiation or which have a suffi­
ciently short half-life so as not to emit a significant 
25 amount of beta or gamma radiation are listed in Table I 
without an asterisk; those marked with an asterisk in 





ELEM ENTS HAVING ACCEPTABLE NUCLEAR PROPERTIES 
FOR USE IN RADIOTHERAPEUTIC GLASS M ICROSPHERES
_ _  — C N O F  —
Na Mg AI Si — — — —
K — — Ti* V — Mn — — — Cu* — Ga Ge* — — — —
_ _  — Zr* Nb — — _ _ _ _  - _ _ I  —
_ _  _ _  _ _ _  _ _ _ _  — — Pb — — — —
between about 1 and about 17 wt. % alumina, between 
about 5 and about 9 wt. % magnesia and between about 
2 and about 10 wt. % phosphorus pentoxide. The den- 40 
sity of the glasses incorporating phosphorus is prefera­
bly within the range of about 2.2 to about 2.7 grams/cc.
The microspheres of the present invention may com­
prise essentially void-free glass microspheres, micro­
shells, i.e., microspheres having a hollow core or glass 45 
microspheres having a “foam-like” structure where the 
microsphere has a plurality of hollow cells. Microshells 
and microspheres having a plurality of hollow cells may 
be preferred where it is desired to employ a micro­
sphere having a density substantially less than that of 50 
the essentially void-free microsphere.
Whether the microspheres of the present invention 
are essentially void-free, microshells, or have a plurality 
of hollow cells, it is preferred that the microspheres be 
substantially spherical, i.e., there are no sharp edges or 55 
points that would cause the microsphere to lodge in a 
location other than that desired. In this context, elipsoi- 
dal and other similarly shaped particles that do not have 
sharp edges or points would be considered to be sub­
stantially spherical in shape. 60
In a preferred embodiment of the present invention, 
the constituent elements of the microspheres are chosen 
so that when administered to the patient, the micro­
spheres emit a therapeutic intensity and amount of 
short-range (e.g., a penetration of the tissue on the order 65 
of about several millimeters or less) beta or gamma 
radiation but will not emit a significant amount of un­
wanted beta or gamma radiation which could have a
In accordance with the present invention, the constit­
uent elements of the glass may be chosen so that the 
radiation may be tailored to deliver a radiation profile 
that is ideally suited for a particular treatment. For 
instance, in some instances it may be preferred to em­
ploy a radiotherapeutic product with short-lived beta 
emitter Y-90, while in others it may be preferred to 
utilize the longer-lived beta emitter P-32 or a product 
that has both components. In other instances, it may be 
desirable to employ a radiotherapeutic product with a 
gamma emitting isotope or a mixture of beta and gamma 
emitting isotopes. The microspheres of the present in­
vention permit this versatility: a combination of ele­
ments having the desired radiation emission profile may 
be incorporated into the glass material. In a preferred 
embodiment, a beta emitter and/or a low energy 
gamma emitting nuclide is incorporated into the micro­
spheres. In a most preferred embodiment, yttrium and­
/o r phosphorus are incorporated into the microspheres; 
P-32 emits pure beta radiation and Y-90 emits nearly 
pure beta radiation which will spare healthy tissue re­
mote from the tumor site in which the microsphere is 
embedded.
The constituent elements of the microspheres of the 
present invention are also preferably chosen so that the 
microsphere does not contain any significant amount of 
elements which have a large cross-section for neutrons. 
An example of one such element that has a large cross- 
section for neutrons is boron which has a cross-section
of 3837 barns. In a most preferred embodiment, the 
microspheres do not contain a significant amount of any 
elements that have a cross-section for neutrons greater 
than about 200 barns.
The radiation dosage delivered through the use of the 5 
activated microspheres upon administration to the pa­
tient can be varied by controlling the number of micro­
spheres administered and by controlling the amount of 
radiation emitting isotopes contained by the micro- 
spheres. The amount of radiation emitting isotopes con- 10 
tained by the microspheres is affected by two factors: 
the amount of the stable element that will be converted 
to a radioelement by irradiation, and the length of time 
of irradiation. Preferably, the microspheres are irradi­
ated for a short period of time with an intense thermal 15 
neutron flux generated by a nuclear fission reactor in­
stead of being irradiated for a significantly longer per­
iod of time with a lesser neutron flux. This technique of 
a short, intense irradiation of the microsphere is particu­
larly preferred where one or more of the constituent 20 
elements of the microsphere has an undesired radiation 
profile and a half-life that is significantly greater than 
those constituent elements having a desired radiation 
profile. Thus, the manner of irradiation may be con­
trolled in such a manner to impart the microsphere with 25 
a therapeutic intensity and amount of radiation while 
also minimizing the amount of undesired radiation.
The microspheres of the present invention may be 
processed to have a size that is appropriate for the ther­
apeutic application. The characteristics of the tissue in 30 
which the microspheres will be embedded generally 
dictate the appropriate size of the microspheres to be 
employed. Generally, microspheres having a size some­
where within the range of about 5 to about 75 microme­
ters are employed for therapeutic applications and in 35 
many cases it is preferred that the microspheres have a 
size somewhere within the range of about 5 to about 50 
micrometers. For instance, in the treatment of liver 
cancer, it is preferred to employ microspheres having a 
size substantially within the range of about 20 to about 40 
30 micrometers; microspheres of this size are small 
enough to be conveniently delivered to the liver 
through the hepatic artery but are too large to pass 
through the capillary bed of the liver.
The microspheres may be administered to the patient 45 
through the use of catheters either alone or in combina­
tion with vasoconstricting agents or by any other means 
of administration that effectively causes the micro­
spheres to become embedded in the cancerous or tumor 
bearing tissue. For purposes of administration, the mi- 50 
crospheres are preferably suspended in a medium that 
has a sufficient density or viscosity that prevents the 
microspheres from settling out of suspension during the 
administration procedure. Presently preferred liquid 
vehicles for suspension of the microspheres include 55 
polyvinylpyrrolidone (PVP), sold under the trade des­
ignation Plasdone K-30 and Povidone by GAF Corp, a 
contrast media sold under the trade designation Metri- 
zamide by Nyegard & Co. of Oslo, Norway, a contrast 
media sold under the trade designation Renografin 76 60 
by E. R. Squibb & Co., 50% dextrose solutions and 
saline.
The microspheres of the present invention may be 
prepared from a homogenous mixture of powders (i.e., 
the batch) that is melted to form the desired glass com- 65 
position. The exact chemical compounds or raw materi­
als used for the batch is not critical so long as they 
provide the necessary oxides in the correct proportion
for the melt composition being prepared. For instance, 
if a YAS glass is being made, then yttria, alumina, and 
silica powders could be used as the batch raw materials. 
The purity of each raw material is preferably greater 
than 99.9%. After either dry or wet mixing of the pow­
ders to achieve a homogeneous mixture, the mixture 
may be placed in a platinum crucible for melting. High 
purity alumina crucibles can also be used if at least small 
amounts of alumina can be tolerated in the glass being 
made. The crucibles containing the powdered batch are 
then placed in an electric furnace which is heated 1500° 
to 1600° C., depending upon the composition. In this 
temperature range, the batch melts to form a liquid 
which is stirred several times to improve its chemical 
homogeneity. The melt should remain at 1500° to 1600 
C. till all solid material in the batch is totally dissolved, 
usually 2-5 hours being sufficient. When melting and 
stirring is complete, the crucible is removed from the 
furnace and the melt is quickly quenched to a glass by 
pouring the melt onto a cold steel plate or into clean 
water. This procedure breaks the glass into fragments, 
which aids and simplifies crushing the glass to a fine 
powder. The powder is then sized and spheroidized for 
use.
Where it is desired to use microspheres having a 
diameter in the range of about 20 to about 30 microme­
ters as for example in the treatment of liver cancer, it is 
preferred that the quenched and broken glass be first 
crushed to about minus 100 mesh particles using a mor­
tar and pestle. The minus 100 mesh material is then 
ground using a mechanized mortar and pestle or ball 
mill, until it passes a 400 mesh sieve. The particles are 
formed into glass microspheres by introducing the 
—400 mesh particles into a gas/oxygen flame where 
they are melted and a spherical liquid droplet is formed 
by surface tension. The droplets are rapidly cooled 
before they touch any solid object so that, their spheri­
cal shape is retained in the solid product.
Just prior to spheroidizing, the —400 mesh powder is 
rescreened through a 400 mesh sieve to destroy any 
large agglomerates that may have formed during stor­
age. The -400 mesh powder is then placed in a vibra­
tory feeder located above the gas/oxygen burner. The 
powder is slowly vibrated into a vertical glass tube 
which guides the falling powder particles directly into 
the hot flame of a gas/oxygen burner. Any burner capa­
ble of melting —400 mesh particles of the particular 
glass composition being used is satisfactory. A typical 
rate for feeding the powder to the flame is 5 to 25 gm/hr 
with the described apparatus. The flame of the burner is 
directed into a metal container which catches the small 
glass beads as they are expelled from the flame. This 
container can be made of any metal which can with­
stand the heat of the burner and does not contaminate 
the glass. The container needs to be large enough so 
that the molten spheres can cool and become rigid be­
fore hitting any solid surface of the catcher container.
After spheroidization, the glass spheres are collected 
and rescreened. When the microspheres are intended to 
be used in the treatment of liver cancer, the fraction less 
than 30 and greater than 20 micrometers in diameter is 
recovered since this is the desirable size for use in the 
human liver. After screening, the —30/+20 micro­
spheres are examined with an optical microscope and 
are then washed with a weak acid (HC1, for example), 
filtered, and washed several times with reagent grade 







nace in air to 500°-600° C. for 2-6 hours to destroy any 
organic material.
The final step is to examine a representative sample of 
the —30/+20 spheres in a scanning electron micro­
scope to evaluate the size range and shape of the 
spheres. The quantity of undersize spheres (less than 10 
micrometers in diameter) is determined along with the 
concentration of non-spherical particles. The composi­
tion of the spheres can be checked by energy dispersive 
x-ray analysis to confirm that the composition is correct 
and that there is an absence of chemical contamination.
The glass microspheres are then ready for irradiation 
and subsequent administration to the patient.
In accordance with the present invention, the above 
processing steps are merely exemplary and do not in 
any way limit the present invention. For instance, those 
skilled in the art will appreciate the steps involved in 
producing a microshell or a microsphere having a plu­
rality of hollow cells. Similarly, the present inventon is 
not limited to glass microspheres having a size de­
scribed above; the size of the microspheres of the pres­
ent invention may be varied according to the applica- 
tion.
In accordance with a preferred embodiment, tile 
microspheres of the present invention may be advanta­
geously used in the treatment of liver cancer. For this 
purpose, it is presently preferred to use essentially void- 
free YAS glass microspheres having a composition 
lying within the previously identified quadrilateral re­
gion of the yttria alumina-silica composition diagram 
and that have an activity of about 0.2 to about 0.6 
Ci/gm of glass after irradiation. To achieve the desired 
level of activity, the YAS microspheres are irradiated 
for an effective period. For instance, YAS microspheres 
comprising about 40% by weight yttria are irradiated in 
a nuclear reactor to a level of about 3 Ci/gm which 
requires about 75 hours of irradiation at lXlO14 neu- 
trons/cm2sec. Thus, by activating the microspheres to a 
level above the preferred administration range, decay of 
activity of the activated microspheres may occur during 40 
processing and shipment prior to administration to the 
patient and still permit administration within the pre­
ferred range of activity. If microshells or microspheres 
comprising a plurality of hollow cells are used instead 
of solid microspheres, the specific activity after irradia­
tion needs to be higher in order to account for the de­
crease in mass of similarly sized spheres. If it were pre­
ferred to use a glass microsphere containing P-32 in­
stead of Y-90 for the treatment of liver cancer, the spe­
cific activity required through irradiation may be con­
siderably lower than that required for Y-90 micro­
spheres; P-32 has a longer half-life than Y-90 (14.3 days 
vs. 64 hours for Y-90) which results in less decay during 
transit and which causes it to remain active in the body 
longer than Y-90.
The microspheres of the present invention may be 
used in the treatment of liver cancer by introducing a 
catheter into the hepatic artery and administering the 
radioactive microspheres. Preferably, the microspheres 
are suspended in a medium such as Plasdone K-30 or 60 
Metrizamide for purposes of administration. The parti­
cle density in the liver after administration is preferably 
on the order of about 4000 microspheres per gram of 
liver. When administered in this manner, the micro-
to decrease hepatic artery flow to normal liver. Micro­
spheres used in this treatment preferably comprise ei­
ther P-32 or Y-90 because of their short-ranged radia- 
tion.
Other cancerous or tumor bearing tissue may simi­
larly be treated with the microspheres of the present 
invention. Depending upon the application, it may be 
desirable to incorporate a gamma emitting radioisotope 
or a combination of gamma and beta emitting radioiso­
topes into the microsphere. Alternatively, a physical 
mixture of microspheres having different radiation pro­
files may be used in order to tailor the treatment for a 
particular case. For instance, the treatment may com­
prise administration of a physical mixture of two differ- 
15 ent microspheres, the first type containing Y-90 and the 
second type containing P-32.
The following examples illustrate the invention.
EXAMPLE 1
A. Microsphere Preparation
The glass compositions listed in Table II were pre­
pared from reagent grade chemicals. Batches yielding 
50 grams of glass were melted in platinum crucibles in 
an electric furnace at the approximate temperatures in 
Table II. A typical melting cycle required three hours 
for batch additions at 1000° C. and three to four hours 
to refine the melt at the approximate melting tempera­
ture. The crucible containing the melt was quenched in 
25° C. water, after which the resultant glass frit was 
broken from the crucible and ground to —100 mesh. 
The —100 mesh glass powder was then slowly fed by a 
vibrating spatula into an oxygen/propane flame where 
surface tension pulled the molten particles into spheres. 
The flow rates of oxygen and propane were adjusted for 
35 each glass composition so as to yield the highest frac­
tion of spherical particles. After spheroidizing, the mi­
crospheres were wet screened with deionized water, 
rinsed in acetone and dried.
B. Chemical Durability Measurements 
The compositions marked with an asterisk in Table II
were immersed in deionized water at 50 C. and the 
release of elemental phosphorus measured as a function 
of time. Samples of 76 to 150 urn diameter microspheres, 
each sample weighing 0.5 gm, were placed in high den­
sity polyethylene bottles with 25 ml of deionized water. 
The bottles were then placed in an oven at 50° 
C. +  / —5° C. for 7, 15, 30, and 40 days with brisk agita­
tion for 5 seconds on days 2 and 27. After removing a 
sample from the oven, the aqueous phase was filtered 
50 through Whatman #52 filter paper. Each filtrate was 
then fumed with Perchloric acid (70-72%) at 750° C. to 
remove any soluble silica that might interfere with the 
spectrophotometric determination of phosphorus. In 
the determination of phosphorus, the fumed solutions 
were mixed with an acidic ammonium vanadate, ammo­
nium molybdate reagent to form a yellow vanadomo- 
lybdate-phosphoric acid complexs. The concentration 
of phosphorus was calculated from the absorbence of 
the solution measured at 400 nm.
C. Spectrophotometric Determination of Phosphorus 
Samples of 25 ml deionized water in which 0.5 gm of
microspheres had been immersed at 50° C. for 7, 15, 30, 
and 40 days were prepared for determination of phos­
phorus content. Standardized solutions of known phos-
45
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rus concentrations. These values were then multiplied 
by dilution factors and converted to the weight of phos­
phorus confirmed in the sample specimens, shown in 
Table V. Division by the weight of phosphorus in the 
known initial weight of glass yields the wt % of phos­
phorus leached given in Table V.
The calibration curve becomes non-linear at very low 
concentrations. This uncertainty in using the calibration 
line to calculate the phosphorus ppm in solution in­
creases with decreasing phosphorus concentration. One 
ppm standard solutions are 4% in error by the time 
absorbence measurements are converted back to ppm 
values from the calibration curve. This error reaches 
6% for 0.5 ppm phosphorus standard solutions. Testing 
standards of 0.1 ppm phosphorus and converting ab­
sorbence values back to ppm values by the calibration 
curve yields errors up to 22%. Since all solutions tested 
had calculated concentrations of phosphorus greater 
than 0.168 ppm, it is safe to assume the maximum error 
in the wt % phosphorus leached values to be less than 
22%. The error in values decreases as the concentration 
of phosphorus in the test specimen increases.
D. Compositional Overview
The glass compositions evaluated in this example can 
be generally classified as either a modified soda-lime 25 
silica or a magnesium aluminosilicate. In the soda-lime 
compositions, the lime was eliminated so as to preclude 
the formation of unwanted 45Ca, and replaced with 
magnesium and/or potassium. Alumina was added to 
nearly all the compositions (see Table II), to improve 
the chemical durability. Compositions UMR-17 and 
UMR-25 contain zirconia, which significantly improves 
the resistance of other silicate glasses to alkaline attack. 
Manganese dioxide was added to UMR-24 also to im­
prove the resistance to alkaline attack.
In attempts to reduce the melting temperatures and 
viscosity, and to keep the alkali content low, lead oxide 
was included in a number of batches, and the magne­
sium carbonate in the batch was replaced by magnesium 
fluoride. The fluxing ability of the lead oxide additions 
appeared minimal at levels less than 10 wt %. Higher 
additions caused phase separation. The substitution of 
magnesium fluoride for magnesium carbonate during 
batching showed a slight improvement in lowering the 
melt viscosity.
E. Spheroidization
In composition UMR-24 large bubbles developed in 
some of the microspheres during spheroidization. Dur­
ing subsequent wet screening, the hollow microspheres 
could easily be separated from the solid spheres by 
floating the hollow spheres away from the heavier solid 
spheres. The formation of bubbles in glass microspheres 
is of interest as a means of lowering the bulk density of 
the microspheres. Table III lists the density of currently 
used essentially void-free microspheres, and the mea­
sured values for the seven glass compositions evaluated 
in the chemical durability tests. The higher density of 
glass microspheres requires a suspending solution with 
either a higher viscosity or higher density to prevent 
settling of the microspheres prior to their use.
F. Stray Radiation Testing
The compositions evaluated for chemical durability 
were also studied after neutron irradiation to check for 
the emission of undesired radiation and a low, tolerable 
backround of undesireable radiation was found in al­
most all compositions. Only UMR-17 contained a signif­
icant amount of an unwanted radioactive isotope and 









ment of liver cancer. The unwanted radioactive isotope, 
95Zr, formed from the 12 wt % zirconia in the glass. By 
reducing the zirconia to 4 wt %, the unwanted radiation 
was lowered to such a level that UMR-26 is acceptable 
for this application based on this evaluation.
G. Chemical Durability Testing
Results from the elemental phosphorus leaching test 
are shown in FIG. 2. The wt % phosphorus leached 
was calculated from the weight of phosphorus found in 
solution, divided by the initial weight of phosphorus in 
the microspheres. The decrease in phosphorus release 
between glasses UMR-3 and UMR-10 is attributed to 
changing the alkali from sodium to potassium, and to 
the reduction in the total alkali content of the glass with 
a corresponding increase in the silica content. The re­
maining compositions are closely grouped with the high 
zirconia containing glass, UMR-17, and the magnesium 
alumino silicate, UMR-21, showing the lowest phos­
phorus releases.
Any chemical corrosion of the glass microspheres by 
deionized water is expected to change the solution pH. 
To a limited extent the change in pH should be propor­
tional to the degree of chemical reaction. The pH values 
of the solution after 74 days at 50° C. is given in Table 
IV. The higher pH values indicate UMR-3 and UMR- 
25 have significantly reacted with the water relative to 
the other compositions.
In the second durability test, the release of radioac­
tive 32P was measured for the same glasses used in the 
first durability test. In this test, microspheres 46 to 75 
um in diameter were first rinsed in 0.12N HC1 at room 
temperature, rinsed in deionized water and then neutron 
irradiated. After irradiation, the microspheres were 
again rinsed in 0.12N HC1, rinsed in deionized water 
and transferred to vials containing 10 ml of human 
blood plasma at 37° C. Samples of human blood plasma 
(1.1 ml), were removed from the vials periodically and 
their beta radioactivity measured with a liquid scintilla­
tion counter. The activity of subsequent samples was 
corrected for the decreasing volume of plasma in the 
vial. In FIG. 3, the percent radioactive phosphorus 
leached is the radioactivity of phosphorus in solution 
divided by the decaying total of radioactive phosphorus 
in the glass.
Comparison of the phosphorus leaching data in 
FIGS. 1 and 2 show a good correlation in the relative 
ranking of glasses evaluated. The combined information 
gathered in the first durability test and pH testing is 
representative of how compositions performed in the 
second test, thus these methods can be used to accu­
rately screen future compositions without handling 
radioactive samples.
To determine the suitability of glasses based on their 
release of radioactive phosphorus, a maximum value of
0.1% radioactive phosphorus leached after 30 days was 
arbitrarily established. This value represents the esti­
mated maximum extent of leaching f rom a 5% by 
weight phosphorus pentoxide glass which will produce 
radioactive P-32 level below the maximum level which 
a healthy adult can tolerate in his body without adverse 
effect.
In FIG. 3, three compositions satisfy the adopted 
value of 0.1 % radioactive phosphorus leached after 30 
days; they are UMR-21, UMR-17, and UMR-26. As 
previously noted, UMR-17 has undesireable radioactive 
emissions that make it unacceptable for this application. 
UMR-21 is a magnesium alumina silicate composition
5,302,369
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TABLE V-continuedwhich had the lowest release of phosphorus in both 
leaching tests.
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_______________________________________ TABLE II ___________________________________
GLASS COMPOSITIONS PREPARED
Sample __________________ Batch Composition (wt 90 ___________________  Approx. Melting Spheres
Identification S i0 2 AbCh MgO PbO NaiO k 2o P2Os Other Temp. (®C.) Observations Produced
UMR-l 72 3 10 15 1550 pours very slow yes
UMR-2 70.6 2.9 9.8 14.7 2.0 1550 pours very slow yes
•UMR-3 69.2 2.9 9.6 14.4 3.9 1525 pours slow yes
UMR-4 66.6 2.8 9.3 13.9 7.4 1500 pours slow yes
UMR-5 72 1 10 15 2 (Y20 3) 1500 pours slow yes
UMR-6 72 3 10 15 1550 did not melt no
UMR-7 72 1 10 2 15 1550 did not melt no
UMR-8 74 1 8 4 10 5 1550 did not melt no
UMR-9 68.5 2.9 9.5 14.3 4.8 1550 pours very slow yes
•UMR-10 73.1 2.1 8.6 10.8 5.4 1550 unable to pour yes
UMR-l! 1.5 93.5 5 1000 crucible leaked no
UMR-12 35 3 55 7 1350 pours easy no
UMR-13 35 3 50 7 5 1400 phase separated yes+
UMR-14 60 i 5 22 5 5 2 (Y20 3) 1500 not homogeneous no
UMR-15 70 2 9 7 12 1500 pours slow yes-}-
UMR-16 66 i 9 10 9 5 1500 unable to pour yes+
•UMR-17 68 i 3 4 7 5 12 (Z r0 2) 1550 unable to pour yes+
UMR-18 55.8 27.2 12 5 1525 unable to pour yes
UMR-19 52.0 17.6 20.4 10 1550 pours slow yes
UMR-20 22.1
MgF-»
77.9 1300 pours easy no
•UMR-21 53.3 14.9 27.3 4.5 1550 pours slow yes
UMR-22 65.2 2.7 14.0 13.6 4.5 1550 pours slow yes
UMR-23 61.4 2.7 14.0 3.8 13.6 4.5 1525 pours slow yes
•UMR-24 66.2 2.8 9.7 13.8 4.6 2.9 (M n02) 1550 pours very slow yes
•UMR-25 61.4 2.7 14.0 3.8 13.6 4.5 1525 pours slow yes
•UMR-26 61.4 2.7 14.0 13.6 4.5 3.8 (Z r0 2) 1550 pours very slow yes
•Compositions evaluated for chemical durability.
-t- Black and white microspheres, possible reduction of lead during spheridization.
TABLE III
DENSITY OF TYPICAL MICROSPHERE 
M ATERIALS AND SELECTED GLASS SAMPLES 35
Density
Material Sample (g/cm 3)
Plastic (Polystyrene) 1.05












PH OF D EION IZED  WATER
IN CONTACT WITH GLASS M ICROSPHERES 50


























15 0.044 0.0434 6.00 0.724
30 0.079 0.0767 5.93 1.293
40 0.095 0.0918 6.24 1.472
UMR-10 7 0.017 + 0.0357 9.45 0.377
15 0.016+ 0.0337 9.45 0.356
30 0.050 0.0482 9.38 0.513
40 0.042 0.0406 8.39 0.484
UMR-17 7 0.018 0.0188 15.11 0.124
15 0.014 0.0149 9.18 0.163
30 0.020 0.0207 12.79 0.162
40 0.024 0.0244 14.12 0.173
UMR-20 8 0.694* 13.90 126.15 11.02
UMR-21 7 0.013 0.0140 12.65 0.111
15 0.014 0.0149 11.85 0.126
30 0.021 0.0216 12.25 0.176
40 0.017 0.0178 12.02 0.148
UMR-24 7 0.014 0.0149 11.05 0.135
15 0.016 0.0168 10.97 0.153
30 0.022 0.0226 10.97 0.206
40 0.018 0.0188 11.07 0.169
UMR-25 7 0.022 0.0226 10.71 0.211
15 0.024 0.0244 10.75 0.227
30 0.027 0.0273 10.68 0.256
40 0.029 0.0292 10.79 0.270
UMR-26 7 0.020 0.0207 10.77 0.192
15 0.020 0.0207 10.80 0.191
30 0.020 0.0207 10.76 0.192
40 0.021 0.0216 10.69 0.202
4-Samples diluted to 100 ml prior to absorbence measurement. 
•Sample diluted to 1000 ml prior to absorbence measurement.
TABLE V
WT % ELEM ENTAL PHOSPHORUS LEACHING DATA 
Wt of
Ab- Phosphorus (mg) Wt % 65
Sample Time sorbence Calculated Initially Phosphorus
ID (days) at 400 nm in Solution in Glass Leached
UMR-3 7 0.024 0.0244 4.76 0.513
EXAMPLE 2
The glass compositions listed in Table VI were pre­
pared from reagent grade materials. Batches of 25 or 50 
grains were melted in platinum crucibles in an electric 




temperature was allowed for fining and homogenization 
of the melt. The glasses were cast into bars measuring 
approximately 1 x 1 x 6  cm in steel molds and were 
annealed at approximately 800° C. for 8 to 12 hours. 
Excess glass in the crucibles was quenched in water, 
broken from the crucible, and saved for spheroidizing. 
Spheroidization of each of the glasses into microspheres 
was performed according to the procedures of Example
1. Table VI also lists the density, pouring temperature 
and appearance for each of the glasses identified.
The glass compositions listed in Table VI were also 
evaluated for chemical durability with the results being 
provided in Table VII. Table VII provides the dissolu­
tion rate for YAS glass samples 2-8 and for vitreous 
silica as determined in IN HC1 under the conditions 
specified.
FIG. 4 reports the percent radioactive yttrium 
leached from sample YAS-1 over time and under the 
conditions expressed in Table VII. Each point in FIG. 4 
represents the amount of radiation measured in solution 
divided by the initial Y-90 activity, the ratio being ex­
pressed as a percent. When expressed in this manner, it 
is apparent that the amount of Y-90 leached from the 
microsphere is well within the acceptability limit.
In FIG. 5, each point represents the measured activ­
ity of leachate from sample YAS-1 over time and under 
the conditions expressed in Table VII. Also presented 
on this plot is a line representing the half-life of Y-90. 
The high degree of correlation between the points and 
this line demonstrate that there was not a significant 












YAS-1 33 21 46 3.07 1500 Viscous. Clear
Glass
YAS-2 55 20 55 3.81 1550 Fluid
YAS-3 50 20 30 3.65 1550 Fluid, Clear Glass
YAS-4 40 20 40 3.29 1500 Fluid, Clear Glass
YAS-5 25 20 55 2.84 1600 Viscous, Opal Glass
YAS-6 42 25 33 3.42 1500 Fluid, Clear Glass
YAS-7 40 30 30 3.39 1500 Fluid, Clear Glass
YAS-8 40 13 47 3.23 1600 Fluid, Opal Glass
YAS-9 55 15 30 3.81 1600 Fluid, Clear Glass
YAS-1C1 35 35 30 3.30 1600 Fluid, Clear Glass
TABLE VII
DISSOLUTION RATES IN IN HC1 OF
YAS GLASSES AND VITREOUS SILICA
Dissolution Rate (g/cm 2 min)
Glass 6 days @ 50° C. 15 days @ 30' C. 7 days @ 50° C.
YAS-2 54.6 X 10- 7
3 36.2 X 10- 7
4 7.8 X 10- 7 2.8 X 1 0 -7 2.1 X 1 0 -7
5 3.4 X 10- 7
6 28.1 X 10- 7
7 28.3 X 10- 7 5.7 X 1 0 -7 6.8 X 1 0 -7
8 7.2 X 10- 7 3.9 X 1 0 -7 2.8 X 1 0 -7












In view of the above, it will be seen that the several 
objects of the invention are achieved and other advanta­
geous results attained.
As various changes could be made in the above meth­
ods and products, without departing from the scope of 
the invention, it is intended that all matter contained in 
the above description or shown in the accompanying
65
drawings shall be interpreted as illustrative and not in a 
limiting sense.
What is claimed is:
1. A substantially spherical microsphere adapted for 
radiation therapy of a mammal consisting essentially of 
at least one non-radioactive isotope distributed substan­
tially uniformly throughout the microsphere and which, 
upon being subjected to an effective amount of neutron 
irradiation, emits a therapeutic intensity and amount of 
beta or gamma radiation, and a balance of elements 
selected from the group consisting of elements that do 
not become radioactive during neutron irradiation and 
elements that have a half-life that is sufficiently short so 
that the balance of elements does not emit a significant 
amount of beta or gamma radiation at the time of admin­
istration, the microsphere having a chemical durability 
such that subsequent to administration of the micro­
sphere to the mammal, the microsphere will not release 
a significant amount of radiation emitting radioisotope 
into the mammal’s system.
2. A microsphere as set forth in claim 1 wherein said 
isotope is selected from the group consisting of isotopes 
of phosphorus and isotopes of yttrium.
3. A microsphere as set forth in claim 2 wherein said 
balance of elements are selected from the group consist­
ing of carbon, nitrogen, oxygen, fluorine, sodium, alu­
minum, silicon, potassium, vanadium, manganese, gal­
lium, niobium, iodine and lead.
4. A microsphere as set forth in claim 2 wherein said 
microsphere comprises an aluminosilicate glass.
5. A microsphere as set forth in claim 2 wherein said 
microsphere comprises a lead silicate glass.
6. A microsphere as set forth in claim 2 wherein said 
microsphere comprises an yttrium oxide-aluminosilicate 
glass.
7. A microsphere as set forth in claim 1 wherein said 
balance of elements are selected from the group consist­
ing of carbon, nitrogen, oxygen, fluorine, sodium, alu­
minum, silicon, potassium, vanadium, manganese, gal­
lium, niobium, iodine, lead, titanium, copper, germa­
nium, and zirconium.
8. A microsphere as set forth in claim 1 wherein the 
non-radioactive isotope forms a radioisotope having a 
half-life between about 2 and about 30 days upon an 
effective amount of irradiation.
9. A microsphere as set forth in claim 1 wherein said 
diameter is between about 5 and about 75 micrometers.
10. A microsphere as set forth in claim 1 wherein said 
microsphere has a hollow core or a plurality of hollow 
cells.
11. A microsphere as set forth in claim 1 wherein said 
microsphere contains less than about 10% phosphorous 
pentoxide.
12. A microsphere as set forth in claim 1 wherein said 
microsphere contains less than about 10% phosphorous 
pentoxide and has a density between about 2.2 grams/- 
cubic centimeter and 2.7 grams/cubic centimeter.
13. A substantially spherical microsphere adapted for 
radiation therapy of a mammal, said microsphere con­
sisting essentially of a non-radioactive isotope selected 
from the group consisting of yttrium or phosphorus and 
a balance of elements selected from the group consisting 
of carbon, nitrogen, oxygen, flourine, sodium, magne­
sium, aluminum, silicon, potassium, vanadium, manga­
nese, gallium, niobium, lead, titanium, copper, germa­
nium, and zirconium, the microsphere having a chemi­
cal durability such that subsequent to administration of 




not release a significant amount of radiation emitting 
radioisotope into the mammal’s system.
14. A microsphere as set forth in claim 13 wherein 
said microsphere has a diameter between about 5 and 
about 75 micrometers and contains less than about 10% 5 
phosphorous pentoxide.
15. A microsphere as set forth in claim 13 wherein 
said microsphere contains less than about 10% phos­
phorous pentoxide and has a density between about 2.2 
grams/cubic centimeter and 2.7 grams/cubic centime- 10 
ter.
16. A biologically compatible microsphere for radia­
tion therapy of a mammal comprising at least one non- 
radioactive isotope distributed substantially throughout 
the microsphere which upon neutron irradiation forms 15 
a radioisotope which emits a therapeutic intensity and 
amount of beta or gamma radiation and has a half-life 
greater than about 2 and less than about 30 days, and a 
balance of elements selected from the group consisting 
of elements that do not become radioactive upon neu- 20 
tron irradiation and elements that have a half-life that is 
sufficiently short so that the elements do not emit a
significant amount of beta or gamma radiation at the 
time of administration, the microsphere having a chemi­
cal durability such that subsequent to administration of 
the microsphere to the mammal, the microsphere will 
not release a significant amount of the radiation emitting 
radioisotope into the mammal’s system.
17. A microsphere as set forth in claim 16 wherein the 
microsphere has a diameter between about 20 and about 
30 micrometers.
18. A microsphere as set forth in claim 16 wherein the 
microsphere has a hollow core or a plurality of hollow 
cells.
19. A microsphere as set forth in claim 16 wherein the 
balance of elements are selected from the group of ele­
ments consisting of carbon, nitrogen, oxygen, fluorine, 
sodium, magnesium, aluminum, silicon, potassium, va­
nadium, manganese, gallium, niobium, iodine and lead.
20. A microsphere as set forth in claim 16 wherein 
said microsphere contains less than about 10% phos­
phorous pentoxide.
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